Immunophenotypic and genotypic characterisation of multiple myelomas with adverse prognosis characterised by immunohistological expression of the T cell related antigen CD45RO (UCHL-1)

Journal of Clinical Pathology

Volumn 51, Issue 6, 1998, Pages 432-437

  Menke, David M ^a,e   Horny, Hans Peter ^b   Griesser, Henrik ^c   Atkinson, Elizabeth J ^d   Kaiserling, Edwin ^b   Kyle, Robert A ^d  

^a MAYO CLINIC   (United States)

^b UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^c UNIVERSITY OF TORONTO   (Canada)

^d MAYO CLINIC   (United States)

^e NONE   (United States)

Author keywords

CD45RO; Immunohistochemistry; Multiple myeloma; Plasma cells; Pre plasma cell precursors

Indexed keywords

CD20 ANTIGEN; CD3 ANTIGEN; CD45 ANTIGEN;

ADULT; AGED; ANTIGEN EXPRESSION; ANTIGEN RECOGNITION; ARTICLE; B LYMPHOCYTE; BONE MARROW BIOPSY; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GENOTYPE; HUMAN; HUMAN TISSUE; IMMUNOHISTOLOGY; IMMUNOPHENOTYPING; LYMPHOCYTIC INFILTRATION; MALE; MULTIPLE MYELOMA; PLASMA CELL; PRIORITY JOURNAL; PROGNOSIS; STEM CELL;

EID: 0031808622     PISSN: 00219746     EISSN: None     Source Type: Journal    
DOI: 10.1136/jcp.51.6.432     Document Type: Article

References (38)

1. Osterborg A, Steinitz M, Lewin N, et al. Establishment of idiotype bearing B-lymphocyte clones from a patient with monoclonal gammopathy. Blood 1991;78:2642-9.
2. Billadeau D, Ahmann G, Greipp P, et al. The bone marrow of multiple myeloma patients contains B cell populations at different stages of differentiation that are clonally related to the malignant plasma cell. J Exp Med 1993;178:1023-31.
3. MacKenzie MR, Lewis JP. Cytogenetic evidence that the malignant event in multiple myeloma occurs in a precursor lymphocyte. Cancer Genet Cytogenet 1985;17:13-20.
4. Jensen GS, Mant MJ, Belch AJ, et al. Selective expression of CD45 isoforms defines CALLA+ monoclonal B-lineage cells in peripheral blood from myeloma patients as late stage B cells. Blood 1991;78:711-19.
5. Jensen GS, Belch AR, Kherani F, et al. Restricted expression of immunoglobulin light chain mRNA and of the adhesion molecule CDIIb on circulating monoclonal B lineage cells in peripheral blood of myeloma patients. Scand J Immunol 1992;36:843-53.
6. Goto H, Shimazaki C, Ashihara E, et al. Effects of interleukin-3 and interleukin-6 on peripheral blood cells from multiple myeloma patients and their clinical significance. Acta Haematol 1992;88:129-35.
7. Massaia M, Bianchi A, Attisano C, et al. Detection of hyperreactive T cells in multiple myeloma by multivalent cross-linking of the CD3/TCR complex. Blood 1991;78:1770-80.
8. Reibnegger G, Wachter H, Krainer M, et al. Hyperreactive cellular immunity in multiple myeloma [letter]. Blood 1992;79:2174-6.
9. Massaia M, Attisano C, Peola S, et al. Rapid generation of antiplasma cell activity in the bone marrow of myeloma patients by CD3-activated T cells. Blood 1993;82:1787-97.
10. Osterborg A, Janson CH, Bergenbrant S, et al. Peripheral blood T lymphocytes in patients with monoclonal gammopathies: expanded subsets as depicted by capacity to bind to autologous monoclonal immunoglobulins or reactivity with anti-V gene-restricted antibodies. Eur J Haematol 1991;47:185-91.
11. Bergsagel PL, Smith AM, Szczepek A, et al. In multiple myeloma, clonotypic B lymphocytes are detectable among CD19+ peripheral blood cells expressing CD38, CD56, and monotypic Ig light chain. Blood 1995;85:436-47.
12. Omede P, Boccadoro M, Gallone G, et al. Multiple myeloma: increased circulating lymphocytes carrying plasma cell-associated antigens as an indicator of poor survival. Blood 1990;76:1375-9.
13. Mellstedt H, Holm G, Pettersson D, et al. T cells in monoclonal gammopathies. Scand J Haematol 1982;29:57-64.
14. Durie BG, Grogan TM. CALLA-positive myeloma: an aggressive subtype with poor survival. Blood 1985;66:229-32.
15. Grogan TM, Durie BG, Spier CM, et al. Myelomonocytic antigen positive multiple myeloma. Blood 1989;73:763-9.
16. Spier CM, Grogan TM, Durie BG, et al. T-cell antigen-positive multiple myeloma. Mod Pathol 1990;3:302-7.
17. Petruch UR, Horny HP, Kaiserling E. Frequent expression of haemopoietic and non-haemopoietic antigens by neoplastic plasma cell: an immunohistochemical study using formalin-fixed, paraffin-embedded tissue. Histopathology 1992;20:35-40.
18. Hsu SM, Raine L, Fanger H. Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures. J Histochem Cytochem 1981; 29:577-80.
19. Greipp PR, Raymond NM, Kyle RA, et al. Multiple myeloma: significance of plasmablastic subtype in morphological classification. Blood 1985;65:305-10.
20. Epstein J, Xiao HQ, He XY. Markers of multiple hematopoietic-cell lineages in multiple myeloma. N Engl J Med 1990;322:664-8.
21. Poppema S, Lai R, Visser L. Monoclonal antibody OPD4 is reactive with CD45RO, but differs from UCHL1 by the absence of monocyte reactivity. Am J Pathol 1991;139:725-9.
22. Wan JH, Trainor KJ, Brisco MJ, et al. Monoclonality in B cell lymphoma detected in paraffin wax embedded sections using the polymerase chain reaction. J Clin Pathol 1990;43: 888-90.
23. Trainor KJ, Brisco MJ, Wan JH, et al. Gene rearrangement in B- and T-lymphoproliferative disease detected by the polymerase chain reaction. Blood 1991;78:192-6.
24. Caligaris-Cappio F, Bergui L, Tesio L, et al. Identification of malignant plasma cell precursors in the bone marrow of multiple myeloma. J Clin Invest 1985;76:1243-51.
25. Grogan TM, Durie BG, Lomen C, et al. Delineation of a novel pre-B cell component in plasma cell myeloma: immunochemical, immunophenotypic, genotypic, cytologic, cell culture, and kinetic features. Blood 1987;70:932-42.
26. Brown RD, Joshua DE, Ioannidis RA, et al. Serum thymidine kinase as a marker of disease activity in patients with multiple myeloma. Aust NZ J Med 1989;19:226-32.
27. Warburton P, Joshua DH, Gibson J, et al. CD10-(CALLA)-positive lymphocytes in myeloma: evidence that they are a malignant precursor population and are of germinal center origin. Leukemia Lymphoma 1989;1:11-20.
28. Barlogie B, Smallwood L, Smith T, et al. High serum levels of lactic dehydrogenase identify a high-grade lymphoma-like myeloma. Ann Intern Med 1989;110:521-5.
29. Pilarski LM, Mant MJ, Ruether BA. Pre-B cells in peripheral blood of multiple myeloma patients. Blood 1985; 66:416-22.
30. Kay NE, Oken MM, Bone N, et al. Circulating CD19+ blood cell levels in myeloma [letter]. Blood 1995;86:4000.
31. Mellstedt H, Hammarstrom S, Holm G. Monoclonal lymphocyte population in human plasma cell myeloma. Clin Exp Immunol 1974;17:371-84.
32. Bast EJ, van Camp B, Reynaert P, et al. Idiotypic peripheral blood lymphocytes in monoclonal gammopathy. Clin Exp Immunol 1982;47:677-82.
33. Jensen GS, Poppema S, Mant MJ, et al. Transition in CD45 isoform expression during differentiation of normal and abnormal B cells. Int Immunol 1989;1:229-36.
34. Gloghini A, De Paoli P, Gaidano G, et al. High frequency of CD45RO expression in AIDS-related B-cell non-Hodgkin's lymphomas. Am J Clin Pathol 1995;104:680-8.
35. Leo R, Bocker M, Peest D, et al. Multiparameter analyses of normal and malignant human plasma cells: CD38++, CD56+, CD54+, cIg+ is the common phenotype of myeloma cells. Ann Hematol 1992;64:132-9.
36. Dehou MF, Schots R, Lacor P, et al. Diagnostic and prognostic value of the MB2 monoclonal antibody in paraffin-embedded bone marrow sections of patients with multiple myeloma and monoclonal gammopathy of undetermined significance. Am J Clin Pathol 1900;94:287-91.
37. Barlogie B, Epstein J, Alexanian R. Genotypic and phenotypic characteristics of multiple myeloma. Hematol Oncol 1988;6:99-102.
38. Durie BG. The biology of multiple myeloma. Hematol Oncol 1988;6:77-81.